Angels Pharma

Angels Pharma (Suzhou) Co., Ltd., also known as Anji Xiekang, is a clinical-stage biotechnology company focused on the discovery and development of innovative small-molecule kinase inhibitors for oncology. The company's research primarily targets tyrosine kinases that are critical drivers of hematological malignancies and solid tumors. Its lead product candidate, AC003, is a potent second-generation FLT3 inhibitor currently being evaluated in Phase 2 clinical trials for the treatment of relapsed or refractory Acute Myeloid Leukemia (AML). Angels Pharma leverages expertise in precision medicine to address drug resistance in cancer patients, with a pipeline that includes several early-stage kinase inhibitors. Headquartered in Suzhou, China, the company was founded by seasoned industry experts with backgrounds in prominent global pharmaceutical and academic institutions.